France Confirms First Human Shamonda Virus Case After Immunocompromised Patient Dies in Lyon

Shamonda virus belongs to the Orthobunyavirus group, a collection of viruses primarily carried and spread by insects. For decades it was known mainly as a livestock pathogen, transmitted to animals, especially cattle, by biting midges of the genus Culicoides. Researchers first detected the virus in Nigeria in the mid-1960s, and it has since been reported sporadically in cattle in West, East and southern Africa as well as in Japan. Until this year, it had never been confirmed in European farm animals and had never been detected in a human being.

That changed in the summer of 2026. Clinical signs in European livestock were reported from June, and genomic tests on sick cattle in southern Germany, Switzerland and eastern France identified the virus in late July. It was the first confirmation of Shamonda in European farm animals. Since then, authorities have reported detections in a dozen or more European countries, from Austria and Belgium to Spain and Switzerland, as well as in Jersey. The virus has been found most often in cattle, though the World Organisation for Animal Health says it has also been found in horses, alpaca, sheep and goats.

The animal outbreak has had measurable economic effects. A study of nine French dairy farms found that milk output fell by up to 75 percent in affected herds, according to France 24. In infected adult cattle, the main symptoms are fever, lethargy and diarrhoea; dairy cows may also show a significant drop in milk production, according to Sciensano, Belgium's national public health institute. There are currently no commercially available vaccines against Shamonda virus, the World Organisation for Animal Health said.

On October 22, 2026, French health and agriculture authorities announced that a severely immunocompromised patient treated at the Hospices Civils de Lyon had been infected with Shamonda virus and had died in early October. It was the first documented human case of a virus previously found only in animals. The patient had been receiving treatment for a serious illness. Investigations into whether the virus caused or contributed to the death, and into how the infection was acquired, are ongoing. The French ministries said there was no health risk to the general public identified at this time.

Key Facts

ECDC said on October 22 that it was carefully monitoring the situation after French authorities announced the first ever reported human infection with Shamonda virus. The agency said it was in contact with French authorities and European partners to investigate the potential public health implications. The only infection so far had been in a patient receiving treatment for a serious illness that made them more susceptible to infection and complications than the general population. The patient died in early October. The human case follows the first ever detection of Shamonda virus in European farm animals in summer 2026, with clinical signs reported from June and the virus identified in late July.

Al Jazeera reported on October 22 that the French Ministry of Agriculture stressed in a statement that there were no identifiable health risks to the general population at this time. The ministry described the case as an exceptional event that could be explained by the patient's poor health. The French health ministry said there was no reason to talk of a health crisis. WHO Director-General Tedros Adhanom Ghebreyesus said the individual was immunocompromised, which made them more vulnerable to infection and severe disease, and noted that the patient was in an area where the virus was circulating in animals and Culicoides midges were present.

Euronews reported on October 22 that the patient had been treated at the Hospices Civils de Lyon and that preliminary findings linked neurological complications before death to the infection. The French Agriculture Ministry said the brain complications observed in the immunocompromised patient before death were very likely linked to the Shamonda virus infection. The leading hypothesis is that the patient was infected through the bite of a Culicoides midge in eastern France, where the virus had circulated among animals during spring and summer. The specific midge species involved is still unknown, according to ECDC.

France 24 reported on October 22 that the virus had now been found in 14 western European countries, according to an epidemiological bulletin from France's national research institute monitoring animal health. ECDC said the detections in farm animals covered Austria, Belgium, France, Germany, Ireland, Italy, Liechtenstein, Luxembourg, the Netherlands, Portugal, Spain and Switzerland, as well as Jersey. France's weekly animal health surveillance bulletin also listed Slovenia and the United Kingdom's Jersey among the places where the virus had been detected. The exact count varies by source and by reporting date.

Analysis

The first human Shamonda case is a reminder that the line between animal and human health is not fixed. What this really means is that a virus that had been catalogued for decades as a livestock pathogen can, under the right conditions, find a human host. The conditions here were specific: a severely immunocompromised patient, a region where the virus was circulating in animals, and the presence of Culicoides midges. That combination does not describe the general population. It does, however, describe a plausible route of exposure that public health agencies must now investigate.

The French authorities have been careful to avoid alarm. They called the death an exceptional event and said there was no health risk to the general public identified at this time. That language is appropriate given the evidence so far. A single human infection in a severely ill patient is not the same as sustained human-to-human transmission. There is no indication in the materials that the virus has spread from the patient to anyone else. The more important question is whether the virus is circulating more widely in midges and animals than current testing has shown. ECDC's push to strengthen testing capacity suggests that agencies are treating that question seriously.

The bigger picture here is that Europe's changing animal health landscape is producing new human health questions. Shamonda was first confirmed in European farm animals in late July 2026 and has since been reported across a dozen or more countries. The milk production losses of up to 75 percent on nine French dairy farms show that the economic impact on livestock can be sharp. The absence of a commercial vaccine limits the tools available for controlling the animal outbreak. The investigation into the patient's death will matter for how agencies communicate risk. If the neurological complications are confirmed as very likely linked to Shamonda infection, the case will stand as a documented example of severe human disease from an orthobunyavirus not previously known to infect people. Either way, the response should be proportional, and the French ministries have said there is no reason to talk of a health crisis.

Why It Matters

The case matters because it expands the known host range of Shamonda virus. Until this year, the virus was considered non-transmissible to humans. French authorities said that despite circulating in Africa and Asia for several decades, the virus had never previously been detected in humans. A first human case does not prove that the virus is becoming more dangerous, but it does show that the species barrier is not absolute. For clinicians in affected regions, the case is a signal to consider Shamonda in patients with compatible symptoms and exposure to midges or livestock.

It also matters for animal health and food supply. The virus has been detected in cattle, horses, alpaca, sheep and goats. In dairy herds, milk losses of up to 75 percent are a direct economic hit. With no commercial vaccine, farmers and veterinarians must rely on midge control, surveillance and movement management. The involvement of WOAH, ECDC, the European Commission, EFSA and the EU Reference Laboratory shows that the response is already crossing the animal and human health divide. That is the right approach for a pathogen spread by insects that feed on both animals and people.

Next Up

The immediate next step is the completion of clinical, laboratory and epidemiological investigations into the patient's infection and death. French authorities, WHO and ECDC are working to determine whether the virus caused or contributed to the death and how the infection was acquired. ECDC is also working with the European Commission, EFSA and the EU Reference Laboratory to strengthen testing capacity and support member states in identifying any other potential cases. Surveillance will focus on midges and farm animals in affected countries, especially in eastern France where the patient is believed to have been infected. Because biting midges are generally most active from spring to autumn, the coming months will be important for tracking whether the virus persists or expands. The World Health Organization and ECDC have been notified, and further updates are expected as investigations proceed.